# Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

> **NCT03314740** · PHASE2 · COMPLETED · sponsor: **Mario Negri Institute for Pharmacological Research** · enrollment: 123 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Cediranib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03314740
- **Lead sponsor:** Mario Negri Institute for Pharmacological Research
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-12
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2025-01-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314740, "Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03314740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*